NCT00330733View on ClinicalTrials.gov

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions
AtherosclerosisCardiovascular DiseaseInflammationInsulin ResistanceNoninsulin-dependent Diabetes Mellitus
Interventions
DRUG

Salsalate

Participants were randomized to 12-week treatment with up to 4 g/day.

DRUG

Placebo

Participants were randomized to 12-week treatment matching the active salsalate arm.

Trial Locations (1)

85012

Carl T. Hayden VA Medical Center, Phoenix

All Listed Sponsors
collaborator

Joslin Diabetes Center

OTHER

lead

VA Office of Research and Development

FED

NCT00330733 - Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk | Biotech Hunter | Biotech Hunter